Alnylam Pharmaceuticals

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Established: 2002-01-01

Employees: -

Market Cap: $35.9B

Website: http://www.alnylam.com/

Clinical Trials

A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

Phase 1

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions: Drug: Sterile Normal Saline (0.9% NaCl)
Drug: ALN-CC5

First Posted Date: 2015-02-02

Last Posted Date: 2020-03-30

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT02352493

Locations: 🇬🇧
Richmond Pharmacology, London, United Kingdom
🇬🇧
Clinical Trial Site, Leeds, United Kingdom
🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Phase 3

Completed

Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Amyloid Neuropathies, Familial
Amyloidosis, Hereditary, Transthyretin-Related
Amyloid Neuropathies
Familial Transthyretin Cardiac Amyloidosis
Amyloidosis, Hereditary

Interventions: Drug: Revusiran (ALN-TTRSC)
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2014-12-18

Last Posted Date: 2018-07-18

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 206

Registration Number: NCT02319005

Locations: 🇬🇧
Clinical Trial Site, Tooting, United Kingdom

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Phase 1

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Sterile Normal Saline (0.9% NaCl)
Drug: ALN-PCSSC

First Posted Date: 2014-12-11

Last Posted Date: 2015-12-17

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 70

Registration Number: NCT02314442

Locations: 🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom
🇬🇧
Richmond Pharmacology, London, United Kingdom

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Phase 2

Completed

Conditions: TTR-mediated Amyloidosis

Interventions: Drug: Revusiran (ALN-TTRSC)

First Posted Date: 2014-11-17

Last Posted Date: 2020-07-09

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT02292186

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Completed

Conditions: Familial Amyloidotic Cardiomyopathy (FAC)

First Posted Date: 2014-09-30

Last Posted Date: 2016-07-20

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 1010

Registration Number: NCT02252653

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Completed

Conditions: Acute Hepatic Porphyria

First Posted Date: 2014-09-16

Last Posted Date: 2021-05-17

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 136

Registration Number: NCT02240784

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

Phase 1

Completed

Conditions: Transthyretin (TTR)-Mediated Amyloidosis

Interventions: Drug: patisiran (ALN-TTR02)
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2014-02-03

Last Posted Date: 2015-05-25

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT02053454

Locations: 🇬🇧
Clinical Site, London, United Kingdom

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Phase 2

Completed

Conditions: TTR-mediated Amyloidosis

Interventions: Drug: ALN-TTRSC (revusiran) for subcutaneous administration

First Posted Date: 2013-11-13

Last Posted Date: 2023-03-20

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT01981837

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Phase 2

Completed

Conditions: TTR-mediated Amyloidosis

Interventions: Drug: ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

First Posted Date: 2013-10-14

Last Posted Date: 2024-04-19

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT01961921

Locations: 🇸🇪
Clinical Trial Site, Umeå, Sweden

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Phase 3

Completed

Conditions: TTR-mediated Amyloidosis
Amyloid Neuropathies, Familial
Amyloid Neuropathies
Amyloidosis, Hereditary
Familial Amyloid Polyneuropathies
Amyloidosis, Hereditary, Transthyretin-Related

Interventions: Drug: patisiran (ALN-TTR02)
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2013-10-10

Last Posted Date: 2024-04-22

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 225

Registration Number: NCT01960348

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy